Novel indole-based tambjamine-analogues induce apoptotic lung cancer cell death through p38 mitogen-activated protein kinase activation

Molecular Cancer Therapeutics

Volumn 16, Issue 7, 2017, Pages 1224-1235

  Manuel Manresa, Pilar ^a   Korrodi Gregório, Luís ^a,b   Hernando, Elsa ^c   Villanueva, Alberto ^d   Martínez García, David ^a   Rodilla, Ananda M ^a   Ramos, Ricard ^a   Fardilha, Margarida ^b   Moya, Juan ^a   Quesada, Roberto ^c   Soto Cerrato, Vanessa ^a   Pérez Tomás, Ricardo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF AVEIRO   (Portugal)

^c UNIVERSITY OF BURGOS   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1H INDOLE 2 YL) 3 METHOXY 1H PYRROLE 2 CARBALDEHYDE; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; CASPASE 3; CASPASE 9; CATHEPSIN; CATHEPSIN S; CISPLATIN; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR BETA; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 8; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; POLO LIKE KINASE 1; POLO LIKE KINASE 4; PROSTAGLANDIN SYNTHASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C EPSILON; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PYRROLE DERIVATIVE; TAMBJAMINE K;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL STRESS; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GENE; HUMAN; HUMAN CELL; HYPERPOLARIZATION; LUNG CANCER; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANIMAL; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85021121982     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0752     Document Type: Article

References (53)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013 [cited 2016 Jul 20]. Available from: http://globocan.iarc.fr.
2. Carrera PM, Ormond M. Current practice in and considerations for personalized medicine in lung cancer: from the patient's molecular biology to patient values and preferences. Maturitas 2015;82:94–9.
3. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov 2009;8:69–85.
4. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH. Marine natural products as anticancer drugs. Mol Cancer Ther 2005;4:333–42.
5. Mayer AM, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, et al. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 2010;31:255–65.
6. Carbone M, Irace C, Costagliola F, Castelluccio F, Villani G, Calado G, et al. A new cytotoxic tambjamine alkaloid from the Azorean nudibranch Tambja ceutae. Bioorg Med Chem Lett 2010;20:2668–70.
7. Gale PA, Perez-Tomas R, Quesada R. Anion transporters and biological systems. Acc Chem Res 2013;46:2801–13.
8. Llagostera E, Soto-Cerrato V, Montaner B, Perez-Tomas R. Prodigiosin induces apoptosis by acting on mitochondria in human lung cancer cells. Ann N Y Acad Sci 2003;1010:178–81.
9. Perez-Tomas R, Montaner B, Llagostera E, Soto-Cerrato V. The prodigiosins, proapoptotic drugs with anticancer properties. Biochem Pharmacol 2003;66:1447–52.
10. Soto-Cerrato V, Llagostera E, Montaner B, Scheffer GL, Perez-Tomas R. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem Pharmacol 2004;68:1345–52.
11. Iglesias Hernandez P, Moreno D, Javier AA, Torroba T, Perez-Tomas R, Quesada R. Tambjamine alkaloids and related synthetic analogs: efficient transmembrane anion transporters. Chem Commun 2012;48:1556–8.
12. Hernando E, Soto-Cerrato V, Cortes-Arroyo S, Perez-Tomas R, Quesada R. Transmembrane anion transport and cytotoxicity of synthetic tambjamine analogs. Org Biomol Chem 2014;12:1771–8.
13. Soto-Cerrato V, Manuel-Manresa P, Hernando E, Calabuig-Farinas S, Martinez-Romero A, Fernandez-Duenas V, et al. Facilitated anion transport induces hyperpolarization of the cell membrane that triggers differentiation and cell death in cancer stem cells. J Am Chem Soc 2015;137:15892–8.
14. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009;15:1010–2.
15. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498–504.
16. Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, et al. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. Cancer Res 2014;74:5978–88.
17. Ambrogio C, Gomez-Lopez G, Falcone M, Vidal A, Nadal E, Crosetto N, et al. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nat Med 2016; 22:270–7.
18. Yan R, Yang Y, Zeng Y, Zou G. Cytotoxicity and antibacterial activity of Lindera strychnifolia essential oils and extracts. J Ethnopharmacol 2009; 121:451–5.
19. Zhan M, Qu Q, Wang G, Zhou H. Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL. Pharmazie 2013; 68:955–61.
20. Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, et al. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 2006;29:471–9.
21. Yang Y, Liu X, Huang J, Zhong Y, Mao Z, Xiao H, et al. Inhibition of p38 mitogen-activated protein kinase phosphorylation decrease tert-butyl hydroperoxide-induced apoptosis in human trabecular meshwork cells. Mol Vis 2012;18:2127–36.
22. Dallaporta B, Marchetti P, de Pablo MA, Maisse C, Duc H-T, Métivier D, et al. Plasma membrane potential in thymocyte apoptosis. J Immunol 1999;162:6534–42.
23. Bortner CD, Gómez-Angelats M, Cidlowski JA. Plasma membrane depolarization without repolarization is an early molecular event in anti-Fas-induced apoptosis. J Biol Chem 2001;276:4304–14.
24. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55:178–94.
25. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011;30:87.
26. Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med 2014;65:139–55.
27. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15:49–63.
28. Pavlyukov MS, Antipova NV, Balashova MV, Vinogradova TV, Kopantzev EP, Shakhparonov MI. Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem 2011;286:23296–307.
29. Ko SK, Kim SK, Share A, Lynch VM, Park J, Namkung W, et al. Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells. Nat Chem 2014;6:885–92.
30. Saha T, Hossain MS, Saha D, Lahiri M, Talukdar P. Chloride-mediated apoptosis-inducing activity of Bis(sulfonamide) anionophores. J Am Chem Soc 2016;138:7558–67.
31. Zhao W, Lu M, Zhang Q. Chloride intracellular channel 1 regulates migration and invasion in gastric cancer by triggering the ROS-mediated p38 MAPK signaling pathway. Mol Med Rep 2015;12:8041–7.
32. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537–49.
33. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005;15:11–8.
34. Son Y, Kim S, Chung HT, Pae HO. Reactive oxygen species in the activation of MAP kinases. Methods Enzymol 2013;528:27–48.
35. Tsuchiya T, Tsuno NH, Asakage M, Yamada J, Yoneyama S, Okaji Y, et al. Apoptosis induction by p38 MAPK inhibitor in human colon cancer cells. Hepatogastroenterology 2008;55:930–5.
36. Li QC, Liang Y, Tian Y, Hu GR. Arctigenin induces apoptosis in colon cancer cells through ROS/p38MAPK pathway. J BUON 2016;21:87–94.
37. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004;10:125–9.
38. Bodur C, Kutuk O, Karsli-Uzunbas G, Isimjan TT, Harrison P, Basaga H. Pramanicin analog induces apoptosis in human colon cancer cells: critical roles for Bcl-2, Bim, and p38 MAPK signaling. PLoS One 2013; 8:e56369.
39. Hsiao PW, Chang CC, Liu HF, Tsai CM, Chiu TH, Chao JI. Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol Appl Pharmacol 2007;222:97–104.
40. Liu HF, Hu HC, Chao JI. Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells. Chem Biol Interact 2010;188:535–45.
41. Ahn J, Won M, Choi JH, Kim YS, Jung CR, Im DS, et al. Reactive oxygen species-mediated activation of the Akt/ASK1/p38 signaling cascade and p21(Cip1) downregulation are required for shikonin-induced apoptosis. Apoptosis 2013;18:870–81.
42. Pan J, Chang Q, Wang X, Son Y, Zhang Z, Chen G, et al. Reactive oxygen species-activated Akt/ASK1/p38 signaling pathway in nickel compound-induced apoptosis in BEAS 2B cells. Chem Res Toxicol 2010;23:568–77.
43. Hernandez Losa J, Parada Cobo C, Guinea Viniegra J, Sanchez-Arevalo Lobo VJ, Ramon y Cajal S, Sanchez-Prieto R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003;22:3998–4006.
44. Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005;35:453–63.
45. Garcia-Cano J, Roche O, Cimas FJ, Pascual-Serra R, Ortega-Muelas M, Fernandez-Aroca DM, et al. p38MAPK and chemotherapy: we always need to hear both sides of the story. Front Cell Dev Biol 2016;4:69.
46. Chen X, Duan N, Zhang C, Zhang W. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. J Cancer 2016;7:314–23.
47. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999;344:305–11.
48. Carpenter RL, Lo HW. STAT3 target genes relevant to human cancers. Cancers 2014;6:897–925.
49. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010;429:403–17.
50. Cao W, Xie YH, Li XQ, Zhang XK, Chen YT, Kang R, et al. Burn-induced apoptosis of cardiomyocytes is survivin dependent and regulated by PI3K/ Akt, p38 MAPK and ERK pathways. Basic Res Cardiol 2011;106:1207–20.
51. Changchien JJ, Chen YJ, Huang CH, Cheng TL, Lin SR, Chang LS. Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression. Toxicol Appl Pharmacol 2015;284:33–41.
52. Chen YJ, Liu WH, Kao PH, Wang JJ, Chang LS. Involvement of p38 MAPK- and JNK-modulated expression of Bcl-2 and Bax in Naja nigricollis CMS-9-induced apoptosis of human leukemia K562 cells. Toxicon 2010;55:1306–16.
53. Hui K, Yang Y, Shi K, Luo H, Duan J, An J, et al. The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis in vitro and in vivo. Cancer Lett 2014;354:189–99.